Sanofi is one of the leading companies in the diabetes field, but its flagship insulin product Lantus is now facing growing competition. The firm is looking at new ways of standing out by ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

Sanofi SNY reported third-quarter 2024 adjusted ... driven mainly by higher sales in United States and China. Lantus sales rose 33.8% to €431.0 million. Plavix sales increased 8.3% to €230 ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing ...